Li Bowen, Wang Daoyun, Zhang Chengye, Wang Yadong, Huang Zhicheng, Yang Libing, Yang Huaxia, Liang Naixin, Li Shanqing, Liu Zhihua
Department of Thoracic Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Institute for Immunology, School of Basic Medical Sciences Tsinghua University Beijing China.
Imeta. 2024 Aug 25;3(5):e232. doi: 10.1002/imt2.232. eCollection 2024 Oct.
Microbes play a significant role in human tumor development and profoundly impact treatment efficacy, particularly in immunotherapy. The respiratory tract extensively interacts with the external environment and possesses a mucosal immune system. This prompts consideration of the relationship between respiratory microbiota and lung cancer. Advancements in culture-independent techniques have revealed unique communities within the lower respiratory tract. Here, we provide an overview of the respiratory microbiota composition, dysbiosis characteristics in lung cancer patients, and microbiota profiles within lung cancer. We delve into how the lung microbiota contributes to lung cancer onset and progression through direct functions, sustained immune activation, and immunosuppressive mechanisms. Furthermore, we emphasize the clinical utility of respiratory microbiota in prognosis and treatment optimization for lung cancer.
微生物在人类肿瘤发展中发挥着重要作用，并深刻影响治疗效果，尤其是在免疫治疗方面。呼吸道与外部环境广泛相互作用，并拥有黏膜免疫系统。这促使人们思考呼吸道微生物群与肺癌之间的关系。非培养技术的进步揭示了下呼吸道内独特的群落。在此，我们概述了呼吸道微生物群的组成、肺癌患者的菌群失调特征以及肺癌内的微生物群概况。我们深入探讨了肺部微生物群如何通过直接作用、持续的免疫激活和免疫抑制机制促进肺癌的发生和发展。此外，我们强调呼吸道微生物群在肺癌预后和治疗优化方面的临床应用价值。
